Myriad myRisk with riskScore blends analysis of genetic risk factors with clinical and cancer family history to deliver the most comprehensive, clinically actionable results to help providers manage their patients’ risk of cancer. This means more of your patients will benefit from valuable information that can make a difference in health outcomes for themselves and for their families.
Reduce false negatives
At Myriad there is not an acceptable false negative rate. We invest heavily in new technologies and techniques to make sure we minimize the potential for error.
Identifying cancer at an earlier stage provides you important information to better treat your patients and prevent secondary cancers.
Save time and money
Not only will the testing process be painless, the cost of the test is also painless with Myriad. Myriad strives to keep costs low for patients.
Clinically validated tool to estimate risk of breast cancer by assessing a combination of genetic markers, clinical factors, and family history
Analytically validated high-throughput laboratory with 99.98% accuracy10
Industry leading, FDA-reviewed11 variant interpretation program, as part of the BRACAnalysis CDx PMA, with powerful methods unique to Myriad
DeFrancesco et al. Hereditary Cancer Risk Assessment and Genetic Testing in the CommunityPractice Setting. Obstetrics & Gynecology 2018 – published online before print October 10, 2018.
Bellcross CA, et al. Genet Med. 2015;17(1):43–50.
Hartmann, L. C. et al. Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer. N. Engl. J. Med. 340, 77–84 (1999).
Rebbeck, T. R. et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N. Engl. J. Med. 346, 1616–1622 (2002).
Plevritis, S et al. Cost-effectiveness of Screening BRCA1/2 Mutation Carriers With Breast Magnetic Resonance Imaging. JAMA. 295(20), 2374–2384 (2006).
de Jong, A. E. et al. Decrease in mortality in Lynch syndrome families because of surveillance. Gastroenterology 130, 665–671 (2006).
ACOG Committee Opinion: Hereditary Cancer Syndromes and Risk Assessment, No. 634. June 2015, Reaffirmed 2017.
Risk assessment, genetic counseling, and genetic testing for BRCArelated cancer in women: U.S. Preventive Services Task Force recommendation statement. JAMA. 2019;322(7):652-665. doi:10.1001/jama.2019.10987
Judkins T. et al. Development and analytical validation of a 25-gene next generation sequencing panel that includes BRCA1 and BRCA2 genes to assess hereditary cancer risk; BMC Cancer, 2014.
U.S. Food and Drug Administration, Center for Devices and Radiological Health (CDRH). BRACAnalysis CDxTM approval letter, December 19, 2014. Retrieved November 7, 2018, from http://www.accessdata.fda.gov/cdrh_docs/pdf14/P140020A.pdf.
Mersch J, et al. Prevalence of Variant Reclassification Following Hereditary Cancer Genetic Testing. JAMA – published online September 25, 2018.